Filing Details

Accession Number:
0001144204-14-008735
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-02-13 19:23:53
Reporting Period:
2011-12-27
Filing Date:
2014-02-13
Accepted Time:
2014-02-13 19:23:53
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1335103 Protea Biosciences Group Inc. NONE Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1529365 Scott Segal 955 Hartman Run Road
Morgantown WV 26507
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.0001 Per Share ("Common Stock") Acquisiton 2011-12-27 50,000 $2.00 1,569,123 No 4 P Direct
Common Stock Acquisiton 2013-07-23 388,038 $0.50 1,957,161 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Warrant Acquisiton 2011-12-27 25,000 $0.00 25,000 $2.25
Common Stock Warrant Acquisiton 2013-07-23 291,029 $0.00 291,029 $1.10
Common Stock Convertible Notes Disposition 2013-07-23 388,038 $194,019.00 0 $0.50
Common Stock Stock Option Acquisiton 2008-05-30 100,000 $150,000.00 100,000 $1.50
Common Stock Stock Option Acquisiton 2013-03-22 218,750 $120,313.00 218,750 $0.55
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
933,334 2011-12-27 2016-12-27 No 4 P Direct
1,224,363 2013-06-30 2018-07-23 No 4 P Direct
1,224,363 2013-07-23 2013-07-23 No 4 C Direct
1,324,363 2008-05-30 2018-05-30 No 4 A Direct
1,209,779 2013-03-22 2023-03-22 No 4 A Direct
Footnotes
  1. On December 27, 2011 (the "December Closing Date"), the Company issued to Scott Segal (the "Reporting Person") one unit (the "Unit"), consisting of 50,000 shares of the Company's common stock, at a price of $2.00 per share, and a warrant (the "Warrant") to purchase 25,000 shares of Common Stock at an exercise price of $2.25 per share.
  2. On April 16, 2012, the Company issued a Convertible Promissory Note to the Reporting Person in the aggregate principal amount of $100,000. On September 25, 2012 the Company issued a convertible promissory note to the Reporting Person in the aggregate principal amount of $75,000. On March 22, 2013, the Company approved a reduction in the conversion price to $0.50 per share. On June 30, 2013, pursuant to the terms and conditions of a Conversion Agreement, dated June 18, 2013, outstanding principal and interest equal to $194,019 was converted into 388,038 shares of common stock.
  3. Pursuant to the Conversion Agreement, upon conversion of the April Note and September Note, the Company agreed to issue a warrant to purchase 75% of the number of shares into which the notes are convertible.
  4. Represents shares vested as of February 10, 2014.
  5. Reflects the expiration of previously reported warrants to purchase 333,334 shares of common stock held by the Reporting Person.